Viral Vectors & Plasmid DNA Manufacturing Market

Viral Vectors & Plasmid DNA Manufacturing Market Size to Hit US$ 1.3 Bn By 2027 Viral Vectors & Plasmid DNA Manufacturing Market Size, Growth, Trends Analysis, Market Scope, Segment Forecasts, Regional Outlook 2020 - 2027

Share This Article

The viral vectors & plasmid DNA manufacturing market size is expected to hit around US$ 5 billion by 2027 growing at a CAGR of 4% from 2020 to 2027. The report contains 150+ pages with detailed analysis.

The base year for the study has been considered 2020, the historic year 2018, and 2019, the forecast period considered is from 2020 to 2027. The viral vectors & plasmid DNA manufacturing market is analyzed on the basis of value (US$ Million), volume (Unit), and price (US$/Unit).

Download the Sample Pages of this Report for Better Understanding (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1012

Scope of the Stud

This market report studies market dynamics, status and outlook especially in North America, Europe and Asia-Pacific, Latin America, the Middle East and Africa. This research report offers scenario and forecast (revenue/volume), and categorizes the market by key players and various segment. This report also studies global market prominence, competitive landscape, market share, growth rates market dynamics such as drivers, restraints and opportunities, and distributors and sales channels.

This research study also integrates Industry Chain analysis and Porter’s Five Forces Analysis. Further, this report offers a competitive scenario that comprises collaborations, market concentration rate and expansions, mergers & acquisitions undertaken by companies.

Growth Factors

Viral vectors have become ideal choice for gene transfer due to their efficient gene delivery, high transfection efficiency and stable gene expression. Further, upsurge in registration of clinical trials on viral vector-mediated gene therapy is stimulating inclination for viral vectors in gene transfer. Growing pervasiveness of target disorders and diseases, the accessibility of funding for gene therapy development, current research into viral vector-based cell and gene therapies and efficacy of viral vectors in gene therapy delivery are together supporting the market growth. Unexploited latent in emergent markets is projected to provide worthwhile growth opportunities for participants in this market. Furthermore, groundbreaking development in the vaccinology is fuelling the demand of these vectors to greater extent. Great amount of clinical and preclinical studies assessing the prospective of vectors in these cutting-edge therapies have exhibited favorable results. As a result of this, several investors are attracted towards this area which is making plasmid and viral vector manufacturing market a vigorous sector of investment. Further, it is inspiring fortunate funding activities from both the public and private sectors.

Report Highlights

  • Presently, around two-thirds of the gene therapy research is dedicated to oncology. These different facts have backed the governance of cancer segment over other disease segments
  • Extensive progress made in gene and cell therapy research since the early 1970s and 1980s has accelerated the adoption rate of plasmids and viral vectors for their use in these modern therapies
  • Pharmaceutical and biopharmaceutical companies are expected to collect major share of the global vector market. This is because of the effective launch of viral vector gene therapies and a vigorous pipeline of such therapies that helps growth of pharmaceutical and biopharmaceutical companies during near future.
  • Presently, U.S. and Europe have seemed as vector manufacturing centers despite of the fact that the first 3 gene therapy candidates were granted in Asian countries

Key Players/Manufacturers

This report also provides detailed company profiles of the key market players. This research report also highlights the competitive landscape of the viral vectors & plasmid DNA manufacturing market and ranks noticeable companies as per their occurrence in diverse regions across the globe and crucial developments initiated by them in the market space. This research study also tracks and evaluates competitive developments, such as collaborations, partnerships, and agreements, mergers and acquisitions; novel product introductions and developments, promotion strategies and Research and Development (R&D) activities in the marketplace. The competitive profiling of these players includes business and financial overview, gross margin, production, sales, and recent developments which can aid in assessing competition in the market.

Some of the prominent players in the global viral vectors & plasmid DNA manufacturing market include:

  • Novasep
  • Aldevron
  • MerckWaismanBiomanufacturing
  • Creative Biogene
  • The Cell and Gene Therapy Catapult
  • Cobra Biologics
  • uniQure N.V.
  • Addgene
  • FUJIFILM Holdings Corporation
  • Oxford Biomedicaplc
  • Takara Bio Inc.

Segments Covered in the Report

This research report estimates revenue growth at global, regional, and country levels and offers an analysis of present industry trends in everysub-segment from 2016 to 2027. This research study analyzes market thoroughly by classifying global viral vectors & plasmid DNA manufacturing market report on the basis of different parameters including type of vector, application, workflow, end users, disease, and region:

By Vector Type

  • Adenovirus
  • Plasmid DNA
  • Lentivirus
  • Retrovirus
  • AAV
  • Others

By Application

  • Gene Therapy
  • Antisense &RNAi
  • Cell Therapy
  • Vaccinology

By Workflow

  • Upstream Processing
    • Vector Recovery/Harvesting
    • Vector Amplification & Expansion
  • Downstream Processing
    • Fill-finish
    • Purification

By End-User

  • Biopharmaceutical and Pharmaceutical Companies
  • Research Institutes

By Disease

  • Genetic Disorders
  • Cancer
  • Infectious Diseases
  • Others

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Rest of the World

Research Objective

  • To provide a comprehensive analysis of the viral vectors & plasmid DNA manufacturing industry and its sub-segments in the global market, thereby providing a detailed structure of the industry
  • To provide detailed insights into factors driving and restraining the growth of this global market
  • To provide a distribution chain analysis/value chain for the this market
  • To estimate the market size of the global viral vectors & plasmid DNA manufacturing market where 2019 would be the historical period, 2020 shall be the base year, and 2020 to 2027 will be the forecast period for the study
  • To provide strategic profiling of key companies (manufacturers and distributors) present across the globe, and comprehensively analyze their competitiveness/competitive landscape in this market
  • To analyze the global market in four main geographies, namely, North America, Europe, Asia-Pacific, and the Rest of the World
  • To provide country-wise market value analysis for various segments of the viral vectors & plasmid DNA manufacturing

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers

Chapter 7. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Vector Type

7.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Vector Type, 2020-2027
7.1.1. Adenovirus
7.1.1.1. Market Revenue and Forecast (2016-2027)
7.1.2. Plasmid DNA
7.1.2.1. Market Revenue and Forecast (2016-2027)
7.1.3. Lentivirus
7.1.3.1. Market Revenue and Forecast (2016-2027)
7.1.4. Retrovirus
7.1.4.1. Market Revenue and Forecast (2016-2027)
7.1.5. AAV
7.1.5.1. Market Revenue and Forecast (2016-2027)
7.1.6. Others
7.1.6.1. Market Revenue and Forecast (2016-2027)

Chapter 8. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Application Type

8.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Application Type, 2020-2027
8.1.1. Gene Therapy
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Antisense &RNAi
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Cell Therapy
8.1.3.1. Market Revenue and Forecast (2016-2027)
8.1.4. Vaccinology
8.1.4.1. Market Revenue and Forecast (2016-2027)

Chapter 9. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Workflow Type

9.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Workflow Type, 2020-2027
9.1.1. Upstream Processing (Vector Recovery/Harvesting, Vector Amplification & Expansion)
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Downstream Processing (Fill-finish, Purification)
9.1.2.1. Market Revenue and Forecast (2016-2027)

Chapter 10. Global Viral Vectors & Plasmid DNA Manufacturing Market, By End-User Type

10.1. Viral Vectors & Plasmid DNA Manufacturing Market, by End-User Type, 2020-2027
10.1.1. Biopharmaceutical and Pharmaceutical Companies
10.1.1.1. Market Revenue and Forecast (2016-2027)
10.1.2. Research Institutes
10.1.2.1. Market Revenue and Forecast (2016-2027)

Chapter 11. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Disease

11.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Disease, 2020-2027
11.1.1. Genetic Disorders
11.1.1.1. Market Revenue and Forecast (2016-2027)
11.1.2. Cancer
11.1.2.1. Market Revenue and Forecast (2016-2027)
11.1.3. Infectious Diseases
11.1.3.1. Market Revenue and Forecast (2016-2027)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2016-2027)

Chapter 12. Global Viral Vectors & Plasmid DNA Manufacturing Market, Regional Estimates and Trend Forecast

12.1. North America
12.1.1. Market Revenue and Forecast, by Vector (2016-2027)
12.1.2. Market Revenue and Forecast, by Application (2016-2027)
12.1.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.1.4. Market Revenue and Forecast, by End-User (2016-2027)
12.1.5. Market Revenue and Forecast, by Disease (2016-2027)
12.1.6. U.S.
12.1.6.1. Market Revenue and Forecast, by Vector (2016-2027)
12.1.6.2. Market Revenue and Forecast, by Application (2016-2027)
12.1.6.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.1.6.4. Market Revenue and Forecast, by End-User (2016-2027)
12.1.7. Market Revenue and Forecast, by Disease (2016-2027)
12.1.8. Rest of North America
12.1.8.1. Market Revenue and Forecast, by Vector (2016-2027)
12.1.8.2. Market Revenue and Forecast, by Application (2016-2027)
12.1.8.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.1.8.4. Market Revenue and Forecast, by End-User (2016-2027)
12.1.9. Market Revenue and Forecast, by Disease (2016-2027)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Vector (2016-2027)
12.2.2. Market Revenue and Forecast, by Application (2016-2027)
12.2.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.2.4. Market Revenue and Forecast, by End-User (2016-2027)
12.2.5. Market Revenue and Forecast, by Disease (2016-2027)
12.2.6. UK
12.2.6.1. Market Revenue and Forecast, by Vector (2016-2027)
12.2.6.2. Market Revenue and Forecast, by Application (2016-2027)
12.2.6.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.2.7. Market Revenue and Forecast, by End-User (2016-2027)
12.2.8. Market Revenue and Forecast, by Disease (2016-2027)
12.2.8.1. Market Revenue and Forecast, by Raw Material (2016-2027)
12.2.9. Germany
12.2.9.1. Market Revenue and Forecast, by Vector (2016-2027)
12.2.9.2. Market Revenue and Forecast, by Application (2016-2027)
12.2.9.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.2.10. Market Revenue and Forecast, by End-User (2016-2027)
12.2.11. Market Revenue and Forecast, by Disease (2016-2027)
12.2.12. France
12.2.12.1. Market Revenue and Forecast, by Vector (2016-2027)
12.2.12.2. Market Revenue and Forecast, by Application (2016-2027)
12.2.12.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.2.12.4. Market Revenue and Forecast, by End-User (2016-2027)
12.2.13. Market Revenue and Forecast, by Disease (2016-2027)
12.2.14. Rest of Europe
12.2.14.1. Market Revenue and Forecast, by Vector (2016-2027)
12.2.14.2. Market Revenue and Forecast, by Application (2016-2027)
12.2.14.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.2.14.4. Market Revenue and Forecast, by End-User (2016-2027)
12.2.15. Market Revenue and Forecast, by Disease (2016-2027)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Vector (2016-2027)
12.3.2. Market Revenue and Forecast, by Application (2016-2027)
12.3.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.3.4. Market Revenue and Forecast, by End-User (2016-2027)
12.3.5. Market Revenue and Forecast, by Disease (2016-2027)
12.3.6. India
12.3.6.1. Market Revenue and Forecast, by Vector (2016-2027)
12.3.6.2. Market Revenue and Forecast, by Application (2016-2027)
12.3.6.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.3.6.4. Market Revenue and Forecast, by End-User (2016-2027)
12.3.7. Market Revenue and Forecast, by Disease (2016-2027)
12.3.8. China
12.3.8.1. Market Revenue and Forecast, by Vector (2016-2027)
12.3.8.2. Market Revenue and Forecast, by Application (2016-2027)
12.3.8.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.3.8.4. Market Revenue and Forecast, by End-User (2016-2027)
12.3.9. Market Revenue and Forecast, by Disease (2016-2027)
12.3.10. Japan
12.3.10.1. Market Revenue and Forecast, by Vector (2016-2027)
12.3.10.2. Market Revenue and Forecast, by Application (2016-2027)
12.3.10.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.3.10.4. Market Revenue and Forecast, by End-User (2016-2027)
12.3.10.5. Market Revenue and Forecast, by Disease (2016-2027)
12.3.11. Rest of APAC
12.3.11.1. Market Revenue and Forecast, by Vector (2016-2027)
12.3.11.2. Market Revenue and Forecast, by Application (2016-2027)
12.3.11.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.3.11.4. Market Revenue and Forecast, by End-User (2016-2027)
12.3.11.5. Market Revenue and Forecast, by Disease (2016-2027)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Vector (2016-2027)
12.4.2. Market Revenue and Forecast, by Application (2016-2027)
12.4.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.4.4. Market Revenue and Forecast, by End-User (2016-2027)
12.4.5. Market Revenue and Forecast, by Disease (2016-2027)
12.4.6. GCC
12.4.6.1. Market Revenue and Forecast, by Vector (2016-2027)
12.4.6.2. Market Revenue and Forecast, by Application (2016-2027)
12.4.6.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.4.6.4. Market Revenue and Forecast, by End-User (2016-2027)
12.4.7. Market Revenue and Forecast, by Disease (2016-2027)
12.4.8. North Africa
12.4.8.1. Market Revenue and Forecast, by Vector (2016-2027)
12.4.8.2. Market Revenue and Forecast, by Application (2016-2027)
12.4.8.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.4.8.4. Market Revenue and Forecast, by End-User (2016-2027)
12.4.9. Market Revenue and Forecast, by Disease (2016-2027)
12.4.10. South Africa
12.4.10.1. Market Revenue and Forecast, by Vector (2016-2027)
12.4.10.2. Market Revenue and Forecast, by Application (2016-2027)
12.4.10.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.4.10.4. Market Revenue and Forecast, by End-User (2016-2027)
12.4.10.5. Market Revenue and Forecast, by Disease (2016-2027)
12.4.11. Rest of MEA
12.4.11.1. Market Revenue and Forecast, by Vector (2016-2027)
12.4.11.2. Market Revenue and Forecast, by Application (2016-2027)
12.4.11.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.4.11.4. Market Revenue and Forecast, by End-User (2016-2027)
12.4.11.5. Market Revenue and Forecast, by Disease (2016-2027)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Vector (2016-2027)
12.5.2. Market Revenue and Forecast, by Application (2016-2027)
12.5.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.5.4. Market Revenue and Forecast, by End-User (2016-2027)
12.5.5. Market Revenue and Forecast, by Disease (2016-2027)
12.5.6. Brazil
12.5.6.1. Market Revenue and Forecast, by Vector (2016-2027)
12.5.6.2. Market Revenue and Forecast, by Application (2016-2027)
12.5.6.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.5.6.4. Market Revenue and Forecast, by End-User (2016-2027)
12.5.7. Market Revenue and Forecast, by Disease (2016-2027)
12.5.8. Rest of LATAM
12.5.8.1. Market Revenue and Forecast, by Vector (2016-2027)
12.5.8.2. Market Revenue and Forecast, by Application (2016-2027)
12.5.8.3. Market Revenue and Forecast, by Workflow (2016-2027)
12.5.8.4. Market Revenue and Forecast, by End-User (2016-2027)
12.5.8.5. Market Revenue and Forecast, by Disease (2016-2027)

Chapter 13. Company Profiles

13.1. Novasep
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Aldevron
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Merck Waisman Biomanufacturing
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Creative Biogene
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. The Cell and Gene Therapy Catapult
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Cobra Biologics
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. uniQure N.V.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Addgene
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. FUJIFILM Holdings Corporation
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Oxford Biomedicaplc
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
13.11. Takara Bio Inc.
13.11.1. Company Overview
13.11.2. Product Offerings
13.11.3. Financial Performance
13.11.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions

Chapter 15. Appendix

15.1. About Us
15.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Why Buy this Report?

The purpose of Precedence Research’s viral vectors & plasmid DNA manufacturing market study is to provide stakeholders with a detailed picture of potential barriers and untapped opportunities. The report contains exclusive information to assist businesses in making informed decisions about how to maintain growth throughout the assessment period.

Buy Full Research Report (Single User License US$ 4500) @ https://www.precedenceresearch.com/checkout/1012

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://precedenceresearchnews.wordpress.com

Follow us on LinkedIn | Twitter | Facebook

Precedence Research

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

View all posts by Precedence Research →